Paroxetine in the Treatment of Generalized Social Phobia: Open-Label Treatment and Double-Blind Placebo-Controlled Discontinuation
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
We conducted an 11-week forced-escalation open-label study of paroxetine in the treatment of 36 patients with generalized social phobia. At the mean dosage of 47.9 +/- 6.2 mg/day, 23 of 30 completers (77%) were deemed responders on the basis of a clinician rating of either "very much improved" or "much improved" on the Clinical Global Impressions scale. Duke Social Phobia Scale ratings declined from 35.5 +/- 13.1 at baseline to 19.7 +/- 17.4 at week 11 (p < 0.0005), and Liebowitz Social Anxiety Scale ratings declined from 75.1 +/- 25.4 at baseline to 37.2 +/- 32.5 at week 11 (p < 0.0005). Sixteen responders were randomized to an additional 12 weeks of either paroxetine (with no dosage change) or placebo (after a taper period) on a double-blind basis. To the best of our knowledge, this is the first controlled medication-discontinuation study in social phobia. One of eight patients randomized to continue paroxetine relapsed versus five of eight patients randomized to placebo. These findings call for a double-blind, placebo-controlled treatment study of paroxetine in generalized social phobia. They also suggest that relapse rates are high if medication is discontinued early and that further study is needed to determine (1) the optimal duration of maintenance pharmacotherapy for social phobia and (2) if specific psychotherapeutic interventions before medication discontinuation may prevent relapse.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liebowitz, M. R. (2015) · Modern Trends in Pharmacopsychiatry · doi:10.1159/000414022 · Cited by 2,266
Phenelzine vs Atenolol in Social Phobia: A Placebo-Controlled Comparison
Liebowitz, M. R., Schneier, F., Campeas, R., Hollander, E., Hatterer, J., Fyer, A., Gorman, J., Papp, L., Davies, S., Gully, R., et al. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.49.4.290 · Cited by 444
Cognitive-Behavioral and Pharmacological Treatments of Social Phobia: A Controlled Study
Gelernter, C. S. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810340070009 · Cited by 404
Assessing impairment in patients with panic disorder: the Sheehan Disability Scale
Leon, A. C., Shear, M. K., Portera, L., & Klerman, G. L. (1992) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/bf00788510 · Cited by 319
(1988) · American Journal of Psychiatry · doi:10.1176/ajp.145.12.1521 · Cited by 301
(1993) · American Journal of Psychiatry · doi:10.1176/ajp.150.10.1485 · Cited by 263
Social phobia in general health care: an unrecognised undertreated disabling disorder
Weiller, E., Bisserbe, J. C., Boyer, P., Lepine, J. P., & Lecrubier, Y. (1996) · British Journal of Psychiatry · doi:10.1192/bjp.168.2.169 · Cited by 219
(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.12.1760 · Cited by 44
Research works printed but not linked: 21
- Kessler, 1994, Arch Gen Psychiatry, 51, 8, 10.1001/archpsyc.1994.03950010008002 · DOI · Paper page
- Stein, 1994, Am J Psychiatry, 151, 408, 10.1176/ajp.151.3.408 · DOI · Paper page
- Davidson, 1994, Arch Gen Psychiatry, 51, 975, 10.1001/archpsyc.1994.03950120047008 · DOI · Paper page
- Schneier, 1994, J Clin Psychiatry, 55, 322
- Versiani, 1992, Br J Psychiatry, 161, 353, 10.1192/bjp.161.3.353 · DOI · Paper page
- van Vliet, 1992, Eur Neuropsychopharmacol, 2, 21, 10.1016/0924-977X(92)90032-4 · DOI
- Davidson, 1993, J Clin Psychopharmacol, 13, 423, 10.1097/00004714-199312000-00008 · DOI · Paper page
- Hovens, 1994, J Am Acad Child Adolesc Psychiatry, 33, 476, 10.1097/00004583-199405000-00005 · DOI · Paper page
- Lotufo-Neto, 1994, Addiction, 89, 447, 10.1111/j.1360-0443.1994.tb00925.x · DOI
- van Ameringen, 1993, J Clin Psychiatry, 54, 27
- Black, 1992, J Clin Psychopharmacol, 12, 293, 10.1097/00004714-199208000-00022 · DOI · Paper page
- Schneier, 1992, J Clin Psychopharmacol, 12, 62, 10.1097/00004714-199202000-00018 · DOI · Paper page
- van Ameringen, 1994, J Affect Disord, 31, 141, 10.1016/0165-0327(94)90118-X · DOI
- van Vliet, 1994, Psychopharmacology, 115, 128, 10.1007/BF02244762 · DOI · Paper page
- Katzelnick, 1995, Am J Psychiatry, 152, 1368, 10.1176/ajp.152.9.1368 · DOI · Paper page
- Gelernter, 1992, J Clin Psychiatry, 53, 23
- Heimberg, 1990, J Nerv Ment Dis, 178, 172, 10.1097/00005053-199003000-00004 · DOI · Paper page
- Heimberg, 1993, J Anxiety Disord, 7, 249, 10.1016/0887-6185(93)90006-7 · DOI · Paper page
- Mannuzza, 1995, Arch Gen Psychiatry, 52, 230, 10.1001/archpsyc.1995.03950150062011 · DOI · Paper page
- Watson, 1969, J Consult Clin Psychol, 33, 448, 10.1037/h0027806 · DOI · Paper page
- Mattick, 1989, Behav Ther, 20, 3, 10.1016/S0005-7894(89)80115-7 · DOI · Paper page
Cited by
Psychometric properties of the Social Phobia Inventory (SPIN): New self-rating scale
Connor, K. M., Davidson, J. R. T., Churchill, L. E., Sherwood, A., Weisler, R. H., & Foa, E. (2000) · British Journal of Psychiatry · doi:10.1192/bjp.176.4.379 · Cited by 1,624
Cognitive Behavioral Group Therapy vs Phenelzine Therapy for Social Phobia: 12-Week Outcome
Heimberg, R. G., Liebowitz, M. R., Hope, D. A., Schneier, F. R., Holt, C. S., Welkowitz, L. A., Juster, H. R., Campeas, R., Bruch, M. A., Cloitre, M., et al. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.12.1133 · Cited by 585
The treatment of social anxiety disorder
Rodebaugh, T. L., Holaway, R. M., & Heimberg, R. G. (2004) · Clinical Psychology Review · doi:10.1016/j.cpr.2004.07.007 · Cited by 424
“In studies of placebo-controlled discontinuation with paroxetine (Stein, Veriani, Hair, & Kumar, 2002; Stein et al., 1996) and sertraline (Walker et al.”
BackgroundBourin, M., Chue, P., & Guillon, Y. (2001) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2001.tb00189.x · Cited by 408
Psychological and Pharmacological Treatments of Social Phobia: A Meta-Analysis
Fedoroff, I. C., & Taylor, S. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200106000-00011 · Cited by 396
Metadata
- Authors
- Stein, M. B., Chartier, M. J., Hazen, A. L., Kroft, C. D. L., Chale, R. A., Cote, D., & Walker, J. R.
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 1996-06
- Volume
- 16
- Issue
- 3
- Pages
- 218-222
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W2313023493
- Cited by
- 134
- References
- 8
- FWCI
- 22.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Paroxetine in the Treatment of Generalized Social Phobia: Open-Label Treatment and Double-Blind Placebo-Controlled Discontinuation. https://app.cochat.ai/papers/10.1097/00004714-199606000-00005
- The paper
- Stein, M. B., Chartier, M. J., Hazen, A. L., Kroft, C. D. L., Chale, R. A., Cote, D., & Walker, J. R. (1996). Paroxetine in the Treatment of Generalized Social Phobia: Open-Label Treatment and Double-Blind Placebo-Controlled Discontinuation. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/00004714-199606000-00005
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.